Faster Approval Does Not Mean Faster Reimbursement
Several Factors Can Prolong HTA Decision Time
Securing accelerated assessment for a drug in any regulatory jurisdiction is a major boost for drug companies, but it does not necessarily translate into an earlier reimbursement decision.
You may also be interested in...
France's regulatory agency, ANSM, plans to introduce a faster and more equitable system for access to unapproved medicines for individual patients by streamlining its “temporary use authorization” system.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.